thromboembolic

Description: Since approval, the FDA has received postmarketing safety data on thromboembolic events, including serious and fatal outcomes, in patients treated with Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo). Based on available data, the serious risks including the increase in

Link: http://www.fda.gov/safety/medical-product-safety-information/update-safety-andexxa-astrazeneca-fda-safety-communication
Date: 2025-12-22

Description: Coagulation Factor Xa (Recombinant), Inactivated-ZHZO

Link: http://www.fda.gov/vaccines-blood-biologics/approved-blood-products/coagulation-factor-xa-recombinant-inactivated-zhzo
Date: 2025-12-22

Description: Lists of the Coagulation Factors products

Link: http://www.fda.gov/vaccines-blood-biologics/approved-blood-products/coagulation-factors
Date: 2025-12-22

Description: Treatment of of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.

Link: http://www.fda.gov/vaccines-blood-biologics/approved-blood-products/riastap
Date: 2025-12-22

Description: Plasminogen, Human-tvmh

Link: http://www.fda.gov/vaccines-blood-biologics/approved-blood-products/plasminogen-human-tvmh
Date: 2025-12-22

Description: Pooled Plasma (Human), Solvent/Detergent Treated

Link: http://www.fda.gov/vaccines-blood-biologics/approved-blood-products/pooled-plasma-human-solventdetergent-treated
Date: 2025-12-22

Description: Prothrombin Complex Concentrate, Human-LANS

Link: http://www.fda.gov/vaccines-blood-biologics/approved-blood-products/prothrombin-complex-concentrate-human-lans
Date: 2025-12-22

Description: This page lists Adverse Events and Product Deviation Guidance documents.

Link: http://www.fda.gov/vaccines-blood-biologics/general-biologics-guidances/adverse-events-and-product-deviation-guidances
Date: 2025-12-22